A Phase 2 Study Of Glembatumumab Vedotin an Anti-gpNMB Antibody-Drug Conjugate as Monotherapy or in Combination with Varlilumab In Patients with Advanced Melanoma
Brief description of study
If you have been diagnosed with advanced or metastatic melanoma and have previously received checkpoint inhibitors (i.e., ipilimumab) and/or signal transduction inhibitors (i.e., vemurafenib, dabrafenib and trametinib), you may qualify to participate in a study evaluating the drug glembatumumab vedotin. The main goal of this phase II study is to see whether the drug glembatumumab in combination with pembroluzimab is safe and effective in treating patients who have advanced or metastatic melanoma that have progressed on PD-1 inhibitors.
Clinical Study Identifier: s14-00911
ClinicalTrials.gov Identifier: NCTs14-00911
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
